Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

Biomed Pharmacother. 1989;43(4):237-50. doi: 10.1016/0753-3322(89)90003-6.

Abstract

A new platinum complex, oxalatoplatin or l-OHP, which, at the same metal dose in experimental tests is as efficient as cisplatin, and is more so at a lower metal dose than carboplatin; which is as efficient in human tumors of the testis and ovary as these other analogs, and more so in melanoma and breast cancer; which is not nephrotoxic, cardiotoxic or mutagenic, and hardly hematotoxic and neurotoxic, is described and compared with the above-mentioned platinum complexes. Combined with 5Fu, it induces a high number of remissions in colorectal cancer, and has brought about cures in inoperable gastric cancers. Combined with carboplatin, it has resulted in a high proportion of cures in L1210-carrying mice, which no other two-by-two combination of these complexes has achieved.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Carboplatin
  • Cisplatin / adverse effects
  • Cisplatin / pharmacokinetics
  • Cisplatin / therapeutic use*
  • Drug Evaluation
  • Fluorouracil / therapeutic use
  • Humans
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms, Experimental / drug therapy
  • Organoplatinum Compounds / adverse effects
  • Organoplatinum Compounds / pharmacokinetics
  • Organoplatinum Compounds / therapeutic use*
  • Oxaliplatin
  • Papio

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin
  • Carboplatin
  • Cisplatin
  • Fluorouracil